Progen to license cancer R&D
Wednesday, 18 September, 2002
Drug developer Progen Industries is licensing development rights to a new patented cancer therapy from the University of New South Wales.
The agreement with the university's commercialisation arm, UniQuest, gives Progen exclusive world rights to technology covering a novel drug formulation and delivery mechanism with the potential to treat multiple cancers.
Progen is already in trials with its flagship anti-cancer drug, PI-88. It sees the newly-licensed therapy, labelled PI-166, as a complementary stablemate to PI-88 which will help fill Progen's drug pipeline.
PI-166 is currently in late-stage pre-clinical development and Progen will fund further R&D, including human trials, to provide further validation of the therapy.
Low stress resilience may increase psoriasis risk
Young adults who find it harder to cope with stress are more likely to develop psoriasis later in...
Nano carrier could enable oral insulin for diabetics
A new form of oral insulin utilises a nanoscale material that surrounds individual insulin...
Gentler form of IVF found to improve success rates
The 'soft touch' technique, known as Piezo-ICSI, works by gently penetrating an egg using...